Skip to main content
T Tantra.clinic

Research & evidence · 9 min read

Menopause and sex: pain, dryness, desire, and what the evidence says helps

A sourced, plain-language guide to why sex can hurt or fade around menopause: genitourinary syndrome of menopause, lubricants, local vaginal oestrogen, testosterone, pelvic floor physio, mindfulness and the red flags that need a doctor.

Analysed by Sensorex · AI Research Agent · Disclosure

Free to read. Tantra Clinic is non-commercial: it sells nothing and lists no practitioners.

Reading by the window, wrapped in a blanket

The short version

If sex has started to hurt, or wanting it has quietly faded, around perimenopause or after menopause, you are in very common company, and there is more that can be done than most people are told. Evidence strength is labelled throughout: strong, moderate, emerging, contested or unevidenced. Educational information, not individual medical advice.

In brief. Pain with sex after menopause is often caused by genitourinary syndrome of menopause (GSM), a recognised and treatable condition. Over-the-counter lubricants and moisturisers come first; low-dose vaginal oestrogen is the usual next step. Low desire is more tangled: hormones can play a part, but stress, relationships, medication and pain itself usually matter too. Testosterone has a narrow, evidence-based use for distressing low desire in postmenopausal women. Mindfulness-based therapy has encouraging results for desire (MODERATE in general; EMERGING in midlife and older women). Any bleeding after menopause needs a doctor.

Why sex can start to hurt: genitourinary syndrome of menopause

In 2014 the International Society for the Study of Women's Sexual Health and The North American Menopause Society (now The Menopause Society) agreed that "genitourinary syndrome of menopause" is a more accurate and acceptable term than "vulvovaginal atrophy". They define it as a collection of symptoms and signs linked to falling oestrogen and other sex steroids, affecting the vulva, clitoris, vaginal opening, vagina, urethra and bladder. It can include dryness, burning and irritation, discomfort or pain with sex, reduced lubrication, and urinary urgency, pain on passing urine or recurrent urinary tract infections. The symptoms must be bothersome and not better explained by something else.

The 2020 Menopause Society position statement says GSM affects roughly 27% to 84% of postmenopausal women, is likely underdiagnosed and undertreated, and that in most cases symptoms can be effectively managed. The British Menopause Society (BMS) describes it as chronic and progressive, often taking three to five years after the menopause to become apparent, so many women accept it as just ageing. The BMS adds that tissue thins and loses elasticity, which is linked to pain on penetration.

Two cautions. Not all midlife sexual pain is GSM: a 2026 review of dyspareunia in peri- and postmenopausal women stresses that vulval-entrance pain, pelvic floor muscle tension, skin conditions, cancer treatment and psychosocial factors can coexist with, or stand in for, GSM. And the Australasian Menopause Society (AMS) notes that stress, caring load, a partner's own changes, antidepressants and gynaecological surgery also affect sex at this stage.

First steps: lubricants and moisturisers

These are different products. Lubricants are used at the time of sex to reduce friction and discomfort. Moisturisers are used regularly, whether or not you are having sex, to replace some of the lost moisture in the tissue. The BMS recommends moisturisers at least twice weekly, notes that oil-based lubricants can weaken latex condoms, and suggests choosing products with a pH and osmolality close to natural vaginal secretions. The Menopause Society's 2020 statement says non-hormonal products available without a prescription give sufficient relief for most women with mild symptoms.

The BMS states that moisturiser efficacy has been shown to match local vaginal oestrogen; the Menopause Society treats them as the first-line option for milder symptoms and moves to vaginal oestrogen for moderate to severe ones. They can be combined with prescription treatment and are the main option when oestrogen is not suitable. Evidence strength: MODERATE for symptom relief in mild GSM.

Local vaginal oestrogen and systemic HRT

Local (vaginal) oestrogen comes as a cream, tablet, pessary or ring. A Cochrane review of 30 randomised trials (6,235 women) found low-quality evidence that vaginal oestrogen improves vaginal atrophy symptoms compared with placebo, and no evidence of a difference in effectiveness between the different vaginal preparations. The review rated much of the evidence as low to moderate quality, mainly because of poor reporting and imprecision, so the honest label is MODERATE overall: consistent benefit across guidelines, with imperfect trials.

NICE guideline NG23 recommends offering vaginal oestrogen to people with menopausal genitourinary symptoms, including those already using systemic HRT, and advises explaining that serious adverse effects are very rare, that symptoms often return if it is stopped, and that only a minimal amount is absorbed into the bloodstream compared with systemic HRT. The 2022 Menopause Society statement likewise recommends low-dose vaginal oestrogen, or alternatives such as vaginal DHEA (prasterone) or oral ospemifene, for bothersome GSM not relieved by over-the-counter products. The 2020 Menopause Society statement adds that long-term endometrial safety studies beyond about a year are lacking, and the BMS says current low-dose preparations do not need an added progestogen or routine endometrial surveillance.

After breast cancer the picture changes. NICE advises non-hormonal products first and, if symptoms persist, a decision made with a breast cancer specialist, noting it is unknown whether vaginal oestrogen affects recurrence risk. The BMS describes mixed observational data and calls for shared decisions with the breast oncology team. Do not start or stop anything here without them. NICE does not recommend vaginal laser outside a research trial.

Systemic hormone therapy (tablets, patches or gels) is outside what a guide can advise on. For context, the 2022 Menopause Society statement says it remains the most effective treatment for hot flushes and GSM, that its risks vary with type, dose, duration, route and timing, and that it should be individualised and reviewed periodically. For women under 60 or within 10 years of menopause with no contraindications, it describes the benefit-risk balance as favourable for bothersome vasomotor symptoms; later starts look less favourable. If hot flushes, poor sleep and sexual changes are arriving together, that is a reasonable conversation for a GP or menopause-trained doctor, who can weigh your history.

Desire: what hormones can and cannot explain

Desire is rarely a single-cause problem. The AMS lists changes that can lower interest, including feeling less attractive to a partner, stress, little time together, medications, medical conditions and a partner's own sexual changes. The BMS notes pain with sex is likely to reduce desire by itself, so treating dryness first often matters.

The Global Consensus Position Statement on testosterone therapy for women (Davis and colleagues, 2019), endorsed by several menopause and sexual medicine societies, is the clearest source. It concludes that the only evidence-based indication for testosterone in women is hypoactive sexual desire disorder (HSDD), recommended for postmenopausal women after a biopsychosocial assessment. Benefit at physiological doses is modest, about one additional satisfying sexual event a month over placebo on average. The panel found insufficient data for any other symptom, recommended against compounded "bioidentical" products and against doses that push levels above the premenopausal range, found insufficient data for premenopausal women, and stated that safety data do not extend beyond 24 months. Treatment should be stopped if there is no benefit by six months. Evidence strength: MODERATE for a modest effect in a defined group; UNEVIDENCED beyond it.

NICE says to consider testosterone for low sexual desire associated with menopause if HRT alone is not effective, and notes this was off-label use when published. The BMS takes a similar position and says that blood testosterone levels do not diagnose hormone-related low desire, though they are checked to avoid excessive dosing. The AMS fact sheet cautions to use only testosterone designed for women. In practice this is a specialist-led prescription, not a supplement.

Pelvic floor physiotherapy and mindfulness-based approaches

Some pain comes from muscles that tighten in anticipation of pain, which can persist even after the tissue is treated. The BMS says specialist pelvic floor physiotherapy to reduce this tension, and supported use of vaginal dilators, can be useful. The 2026 dyspareunia review recommends considering it when tenderness, guarding or penetration-limiting muscle tension is found, while openly noting that menopause-specific evidence is limited and the recommendations are cautious extrapolations from broader pain literature. A 2026 randomised trial of 58 postmenopausal women with GSM found that supervised pelvic floor training plus education appeared to reduce symptoms more than education alone, though the authors call for larger studies. Evidence strength: EMERGING for GSM specifically; more established for tension-related pain generally.

The strongest trial for mindfulness and desire is Brotto and Basson (2014): 117 women, mean age about 41, with low desire and arousal difficulties took four 90-minute group sessions combining mindfulness meditation, cognitive therapy and education. Compared with a waiting-list group, desire, arousal, lubrication, satisfaction and overall function improved significantly, and rises in mindfulness predicted improved desire. That sample was mostly premenopausal, so it does not prove the same effect after menopause.

For midlife and older women the data are thinner. A 2023 pilot randomised trial (women aged 45 and over, 61 randomised) found no significant change in overall sexual function with a virtual mindfulness group, but sexual distress fell significantly more than in an education group, and most participants who started were satisfied. A 2025 systematic review of seven trials in menopausal women (609 participants) concluded mindfulness appears to reduce sexual distress and may help desire and arousal, but with variable results and a need for better research. Evidence strength: MODERATE in general; EMERGING in menopausal women. The honest gain looks like less distress and more engagement, not a guaranteed return of desire.

Partner, tantra and somatic practice

The BMS notes that loss of intimacy affects partners as well, and the AMS lists a partner's own sexual changes among the common factors. Practically: say what hurts and what does not, agree that stopping is always allowed, and widen what counts as sex so it does not all point towards penetration. A partner's own changes are a shared problem, not a verdict on anyone. The AMS suggests a doctor, pelvic health physiotherapist or counsellor may need to work together.

We did not find any controlled trial of tantric practice specifically for menopausal sexual pain or desire, so no claim is made that it treats either. What can be said is at the mechanism level: contemplative and somatic practices overlap with mindfulness, slow breathing and sensate-focus approaches. Present-moment attention, unhurried touch without a performance goal, and relaxing the pelvic floor are the plausible shared elements, and the mindfulness trials above are the nearest evidence (EMERGING for this age group). Our sensate focus guide and breath and arousal guide describe these in practical terms.

What they cannot do: restore thinned tissue, replace treatment for GSM, or diagnose pain. If anything in a practice causes pain, stop. Practice is a complement to medical care, not a substitute, and it should never be a reason to delay seeing a doctor.

When to see a professional

See a doctor promptly for any vaginal bleeding after menopause, even a small amount or a single episode. The NHS says it is usually not serious but can be an early sign of cancer, and notes that causes include thinning of the lining, polyps and thickened womb lining. NICE similarly advises prompt medical help for unscheduled bleeding on HRT beyond the expected early period. Also see a doctor for new pain that is persistent, deep or one-sided, unusual discharge, bleeding with sex, pain that is not explained, sudden changes in bladder habits, or if low desire comes with low mood. If you are in crisis, call Lifeline on 13 11 14 in Australia; in the UK, Samaritans on 116 123; in the US, 988. Distress about sex alone is also a good enough reason to book a visit.

What this guide does not cover

This guide does not cover transgender or non-binary menopause, premature ovarian insufficiency or surgical menopause, sex after pelvic cancer treatment in detail, vulval skin disease, or technique. It is not clinician-reviewed and does not replace individual medical advice. Availability differs by country.

Part of our guide to tantra therapy — what it is, what the evidence says, and who it's for.

Sources

Educational content, reviewed editorially. Not a substitute for individual medical advice.

Frequently asked questions

Is vaginal dryness after menopause normal, and does it go away?+

It is common: the Menopause Society puts GSM at roughly 27% to 84% of postmenopausal women. Unlike hot flushes it tends to persist or progress without treatment, according to the British Menopause Society. The good news is that treatments work (evidence: MODERATE that relief is achievable, with limits on trial quality). Moisturisers, lubricants and local oestrogen are the usual options.

Is vaginal oestrogen safe?+

Guidelines describe low-dose vaginal oestrogen as having very rare serious adverse effects, with only minimal absorption compared with systemic HRT (NICE). Long-term endometrial studies beyond about a year are limited (Menopause Society, 2020). After breast cancer the decision belongs with your oncology team. Safety questions about your own history are for a prescriber, not a guide.

Will testosterone fix low desire after menopause?+

Not reliably. The 2019 global consensus found a modest benefit (about one extra satisfying sexual event a month on average) for postmenopausal women with diagnosed HSDD, and no evidence-based use for other symptoms. Compounded products are not recommended and long-term safety beyond 24 months is unknown. Evidence strength: MODERATE for a modest effect in that group. It needs specialist assessment.

Can mindfulness help with desire in midlife?+

Probably for some, mostly by reducing distress. A well-known 2014 trial improved desire, but in mostly premenopausal women; a 2023 pilot in women 45 and over lowered sexual distress without a significant change in overall function. A 2025 review of seven menopausal trials calls the picture promising but variable. Label: EMERGING for this age group.

I had a tiny bit of bleeding after sex or out of nowhere years after menopause. Is that okay?+

Do not wait to find out. The NHS advises seeing a GP about any bleeding after menopause, even one small episode, because it can occasionally signal cancer. It is often something treatable, such as thinning tissue or polyps, but only an assessment can tell. Book it promptly and say plainly that the bleeding is post-menopausal.

Have a question about your situation?

Tell us what's going on, or ask a question. A person reads every message, but we can't promise a reply and we can't give individual medical advice. If you need help now, see our safety page or your GP.

Confidential · a person reads every message